Nansu Zong

Dr. Nansu Zong

Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2022 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
Nansu ZongNansu Zong
Nansu Zong
AWAndrew Wen
Andrew Wen
SMSungrim Moon
Sungrim Moon
SFSunyang Fu
Sunyang Fu
LWLiwei Wang
Liwei Wang
HLHongfang Liu
Hongfang Liu
Computational drug repurposing methods adapt Artificial intelligence (AI) algorithms for the discovery of new applications of approved or investigational drugs. Among the heterogeneous datasets, electronic health records (EHRs) datasets provide rich longitudinal and pathophysiological data that facilitate the generation and validation of drug repurposing. Here, we present an appraisal of recently published research on computational drug repurposing utilizing the EHR. Thirty-three research articles, retrieved from Embase, Medline, Scopus, and Web of Science between January 2000 and January 2022, were included in the final review. Four themes, (1) publication venue, (2) data types and sources, (3) method for data processing and prediction, and (4) targeted disease, validation, and released tools were presented. The review summarized the contribution of EHR used in drug repurposing as well as revealed that the utilization is hindered by the validation, accessibility, and understanding of EHRs. These findings can support researchers in the utilization of medical data resources and the development of computational methods for drug repurposing.

5 May 2022 in JMIR Human Factors
Verified
Journal Article
Open access
MHMing Huang
Ming Huang
AKAditya Khurana
Aditya Khurana
GMGeorge Mastorakos
George Mastorakos
AWAndrew Wen
Andrew Wen
HHHuan He
Huan He
HLHongfang Liu
Hongfang Liu
Background: During the COVID-19 pandemic, patient portals and their message platforms allowed remote access to health care. Utilization patterns in patient messaging during the COVID-19 crisis have not been studied thoroughly. In this work, we propose characterizing patients and their use of asynchronous virtual care for COVID-19 via a retrospective analysis of patient portal messages. Objective: This study aimed to perform a retrospective analysis of portal messages to probe asynchronous patient responses to the COVID-19 crisis. Methods: We collected over 2 million patient-generated messages (PGMs) at Mayo Clinic during February 1 to August 31, 2020. We analyzed descriptive statistics on PGMs related to COVID-19 and incorporated patients’ sociodemographic factors into the analysis. We analyzed the PGMs on COVID-19 in terms of COVID-19–related care (eg, COVID-19 symptom self-assessment and COVID-19 tests and results) and other health issues (eg, appointment cancellation, anxiety, and depression). Results: The majority of PGMs on COVID-19 pertained to COVID-19 symptom self-assessment (42.50%) and COVID-19 tests and results (30.84%). The PGMs related to COVID-19 symptom self-assessment and COVID-19 test results had dynamic patterns and peaks similar to the newly confirmed cases in the United States and in Minnesota. The trend of PGMs related to COVID-19 care plans paralleled trends in newly hospitalized cases and deaths. After an initial peak in March, the PGMs on issues such as appointment cancellations and anxiety regarding COVID-19 displayed a declining trend. The majority of message senders were 30-64 years old, married, female, White, or urban residents. This majority was an even higher proportion among patients who sent portal messages on COVID-19. Conclusions: During the COVID-19 pandemic, patients increased portal messaging utilization to address health care issues about COVID-19 (in particular, symptom self-assessment and tests and results). Trends in message usage closely followed national trends in new cases and hospitalizations. There is a wide disparity for minority and rural populations in the use of PGMs for addressing the COVID-19 crisis.

26 December 2022 in Clinical and Translational Science
Verified
Journal Article
Open access
SFSunyang Fu
Sunyang Fu
LWLiwei Wang
Liwei Wang
SMSungrim Moon
Sungrim Moon
Nansu ZongNansu Zong
Nansu Zong
HHHuan He
Huan He
HLHongfang Liu
Hongfang Liu
An increasing number of studies have reported using natural language processing (NLP) to assist observational research by extracting clinical information from electronic health records (EHRs). Currently, no standardized reporting guidelines for NLP‐assisted observational studies exist. The absence of detailed reporting guidelines may create ambiguity in the use of NLP‐derived content, knowledge gaps in the current research reporting practices, and reproducibility challenges. To address these issues, we conducted a scoping review of NLP‐assisted observational clinical studies and examined their reporting practices, focusing on NLP methodology and evaluation. Through our investigation, we discovered a high variation regarding the reporting practices, such as inconsistent use of references for measurement studies, variation in the reporting location (reference, appendix, and manuscript), and different granularity of NLP methodology and evaluation details. To promote the wide adoption and utilization of NLP solutions in clinical research, we outline several perspectives that align with the six principles released by the World Health Organization (WHO) that guide the ethical use of artificial intelligence for health.

25 May 2021 in JMIR Medical Informatics
Verified
Journal Article
Open access
Nansu ZongNansu Zong
Nansu Zong
VNVictoria Ngo
Victoria Ngo
DSDaniel J Stone
Daniel J Stone
AWAndrew Wen
Andrew Wen
YZYiqing Zhao
Yiqing Zhao
GJGuoqian Jiang
Guoqian Jiang
Background: Precision oncology has the potential to leverage clinical and genomic data in advancing disease prevention, diagnosis, and treatment. A key research area focuses on the early detection of primary cancers and potential prediction of cancers of unknown primary in order to facilitate optimal treatment decisions. Objective: This study presents a methodology to harmonize phenotypic and genetic data features to classify primary cancer types and predict cancers of unknown primaries. Methods: We extracted genetic data elements from oncology genetic reports of 1011 patients with cancer and their corresponding phenotypical data from Mayo Clinic’s electronic health records. We modeled both genetic and electronic health record data with HL7 Fast Healthcare Interoperability Resources. The semantic web Resource Description Framework was employed to generate the network-based data representation (ie, patient-phenotypic-genetic network). Based on the Resource Description Framework data graph, Node2vec graph-embedding algorithm was applied to generate features. Multiple machine learning and deep learning backbone models were compared for cancer prediction performance. Results: With 6 machine learning tasks designed in the experiment, we demonstrated the proposed method achieved favorable results in classifying primary cancer types (area under the receiver operating characteristic curve [AUROC] 96.56% for all 9 cancer predictions on average based on the cross-validation) and predicting unknown primaries (AUROC 80.77% for all 8 cancer predictions on average for real-patient validation). To demonstrate the interpretability, 17 phenotypic and genetic features that contributed the most to the prediction of each cancer were identified and validated based on a literature review. Conclusions: Accurate prediction of cancer types can be achieved with existing electronic health record data with satisfactory precision. The integration of genetic reports improves prediction, illustrating the translational values of incorporating genetic tests early at the diagnosis stage for patients with cancer.

2 June 2022 in Briefings in Bioinformatics
Verified
Journal Article
Open access
PDF file
Nansu ZongNansu Zong
Nansu Zong
NLNing Li
Ning Li
AWAndrew Wen
Andrew Wen
VNVictoria Ngo
Victoria Ngo
YYYue Yu
Yue Yu
HLHongfang Liu
Hongfang Liu
Internal validation is the most popular evaluation strategy used for drug–target predictive models. The simple random shuffling in the cross-validation, however, is not always ideal to handle large, diverse and copious datasets as it could potentially introduce bias. Hence, these predictive models cannot be comprehensively evaluated to provide insight into their general performance on a variety of use-cases (e.g. permutations of different levels of connectiveness and categories in drug and target space, as well as validations based on different data sources). In this work, we introduce a benchmark, BETA, that aims to address this gap by (i) providing an extensive multipartite network consisting of 0.97 million biomedical concepts and 8.5 million associations, in addition to 62 million drug–drug and protein–protein similarities and (ii) presenting evaluation strategies that reflect seven cases (i.e. general, screening with different connectivity, target and drug screening based on categories, searching for specific drugs and targets and drug repurposing for specific diseases), a total of seven Tests (consisting of 344 Tasks in total) across multiple sampling and validation strategies. Six state-of-the-art methods covering two broad input data types (chemical structure- and gene sequence-based and network-based) were tested across all the developed Tasks. The best-worst performing cases have been analyzed to demonstrate the ability of the proposed benchmark to identify limitations of the tested methods for running over the benchmark tasks. The results highlight BETA as a benchmark in the selection of computational strategies for drug repurposing and target discovery.

1 April 2025 in npj Health Systems
Verified
Journal Article
Open access
PDF file
SRSivaraman Rajaganapathy
Sivaraman Rajaganapathy
SCShaika Chowdhury
Shaika Chowdhury
XLXiaodi Li
Xiaodi Li
VBVincent Buchner
Vincent Buchner
ZHZhe He
Zhe He
Nansu ZongNansu Zong
Nansu Zong
Synoptic reporting, the documenting of clinical information in a structured manner, enhances patient care by improving accuracy, readability, and report completeness, but imposes significant administrative burdens on physicians. The potential of Large Language Models (LLMs) for automating synoptic reporting remains underexplored. In this study, we explore state-of-the-art LLMs for automatic synoptic reporting, using 7774 pathology reports from 8 cancer types, paired with physician annotated synoptic reports from the Mayo Clinic EHR. We developed a comprehensive automation framework, combining state-of-the-art LLMs, incorporating parameter-efficient optimization, scalable prompt templates, and robust evaluation strategies. We validate our results on both internal and external data, ensuring alignment with pathologist responses. Using our framework, fine-tuned LLAMA-2 achieved BERT F1 scores above 0.86 across all data elements and exceeding 0.94 over 50% (11 of 22) of the data elements, translating to manually assessed mean semantic accuracies of 77% and up to 81% for short clinical reports.